• Publications
  • Influence
In vitro and in vivo anti-Candida activity and toxicology of LY121019.
TLDR
LY121019 (N-p-octyloxybenzoylechinocandin B nucleus) is a semisynthetic antifungal antibiotic that possesses potent anti-Candida activity and caused severe damage to the C. albicans cell. Expand
Antibiotics that inhibit fungal cell wall development.
TLDR
The pradimicins show the ability to bind mannan and thus exert an antifungal effect, and their unique action may provide a better understanding of mannan as a target. Expand
Compound 64716, a New Synthetic Antibacterial Agent
TLDR
Equivalent antibacterial activity along with superior pharmacological properties of 64716 when compared with nalidixic acid lead to the conclusion that this new compound is a promising antibacterial agent. Expand
Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental
TLDR
Continuous and intermittent infusion dosage regimens that elicit nonlinear saturation plasma pharmacokinetics of cilofungin were associated with increased antifungal activity against experimental disseminated candidiasis in persistently granulocytopenic rabbits. Expand
Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B.
TLDR
A series of studies that were carried out on derivatives of the antifungal agent echinocandin B involving enzymatic deacylation of the ECB molecule and synthesis of analogues of ECB by chemical reacylation led to the development of LY 121019, which has excellent efficacy and minimal toxicity in laboratory animals. Expand
Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB.
TLDR
Echinocandin B (ECB) is a lipopeptide composed of a complex cyclic peptide acylated at the N-terminus by linoleic acid which correlated well with in vitro and in vivo activities and was likewise influenced by the structure of the side chain. Expand
Anti‐Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal Antibiotic a
TLDR
In vitro anti-Candida activity of LY121019 and the effectiveness of this novel antifungal antibiotic against experimental Candida infections are reviewed and results of toxicological studies on LY 121019 are summarized. Expand
A9145, a new adenine-containing antifungal antibiotic. II. Biological activity.
TLDR
A combination of amphotericin B and A9145 caused a possible synergistic effect against C. albicans in vitro and an additive effect in vivo, and showed weak in vitro activity against Candida al bicans in SABOURAUD'S medium, but was strongly inhibitory in a chemically defined medium. Expand
Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.
TLDR
It is concluded that following a single dose of cilofungin, the compound is rapidly cleared via first-order kinetics and does not penetrate into the central nervous system, whereas following CI, cil ofungin exhibits nonlinear saturable kinetics, is slowly cleared, and significantly penetrates into central nervousSystem tissues. Expand
...
1
2
3
4
...